Resmetirom for NASH with Liver Fibrosis | NEJM

Currently, no pharmacotherapies are approved for nonalcoholic steatohepatitis. Resmetirom is an oral, liver-directed, THR-β-selective agonist in development for NASH.
Research findings are summarized in a new Quick Take video.
To see the full article, follow this link: nej.md/4bHd7iT
#hepatology #medicalresearch #medicaleducation

[@adithyavikram7]

What is the role of Pioglitazone in Mash with type 2 Dm.

[@user-kv4si9wy8f]

Is there any medicine for hepatic chronic liver disease and cirrhosis of the liver ?

[@rahulmalik4887]

Is it used in alcohol hepatitis

[@adithyavikram7]

Whether this new drug has role in cryptogenic hepatic steatosis.

[@adithyavikram7]

Good news hope that this drug comes to market with reasonable price which patient can afford,by the we have many cases of Mash.Nash is old term ,new term is Mash.

[@iftikharkazi]

New term is MASLD. Cost is approx 50K USD per year per person

[@Cosmo-Kramer]

@@iftikharkazi Or you could just go Carnivore and reverse it naturally.